SEC Form 4 · accession 0000899243-17-028858
Corvus Pharmaceuticals, Inc. · CRVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Erik J. Verner
Officer — V.P., Chemistry Research
Period of report
Dec 13, 2017
Accepted (ET)
Dec 15, 2017 · 4:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001626971
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par valueF1 | holding | — | — | — | 63,773 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $10.60 | Dec 13, 2017 | A | 25,000 | A | — | Dec 13, 2027 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1A portion of these shares is subject to a right of repurchase held by the Issuer.
- F2The underlying shares subject to the option vest and become exercisable as to one-forty eighth (1/48th) of the shares subject to the option in successive, equal monthly installments measured from December 13, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.